Nurix Therapeutics (NRIX) Return on Sales: 2020-2025
Historic Return on Sales for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -2.93%.
- Nurix Therapeutics' Return on Sales rose 21.00% to -2.93% in Q3 2025 from the same period last year, while for Aug 2025 it was -2.93%, marking a year-over-year increase of 21.00%. This contributed to the annual value of -3.55% for FY2024, which is 168.00% down from last year.
- Per Nurix Therapeutics' latest filing, its Return on Sales stood at -2.93% for Q3 2025, which was down 24.69% from -2.35% recorded in Q2 2025.
- Over the past 5 years, Nurix Therapeutics' Return on Sales peaked at -1.79% during Q1 2024, and registered a low of -4.67% during Q4 2022.
- Its 3-year average for Return on Sales is -2.82%, with a median of -2.65% in 2024.
- Its Return on Sales has fluctuated over the past 5 years, first crashed by 283bps in 2021, then surged by 280bps in 2023.
- Over the past 5 years, Nurix Therapeutics' Return on Sales (Quarterly) stood at -3.94% in 2021, then plummeted by 73bps to -4.67% in 2022, then spiked by 280bps to -1.87% in 2023, then tumbled by 168bps to -3.55% in 2024, then grew by 21bps to -2.93% in 2025.
- Its last three reported values are -2.93% in Q3 2025, -2.35% for Q2 2025, and -3.69% during Q1 2025.